Aptar Pharma, a global provider of drug delivery systems, services and active material science services, entered an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ high payload dry powder inhaler, Orbital. Aptar will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbita...